Application of sitagliptin in preparation of medicine for treating Graves eye diseases

By regulating CD4+CTL function and blocking the release of pro-fibrotic and pro-inflammatory factors, sitagliptin addresses the etiological treatment of Graves' ophthalmopathy, achieving safe and effective improvement of the condition.

CN121059609APending Publication Date: 2025-12-05THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511177250.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-21
Publication Date
2025-12-05

AI Technical Summary

Technical Problem

Existing treatments for Graves' ophthalmopathy have low efficacy and significant side effects. There is a lack of safe and effective treatments targeting the underlying cause. CD4+ toxic T lymphocytes play a key role in the development of the disease, leading to tissue damage and fibrosis.

Method used

Sitagliptin, as a CD26 inhibitor, regulates the functional state of CD4+CTLs, blocks their pro-fibrotic and pro-inflammatory factor release, inhibits orbital fibroblast activation, improves orbital fat regeneration and thyroid function, and regulates CD4+CTL cell infiltration, thereby achieving precise intervention in pathological processes.

Benefits of technology

It effectively improves extraocular muscle fibrosis, orbital fat regeneration, and thyroid dysfunction, reduces abnormal CD4+CTL amplification in the spleen, decreases CD4+CTL cell infiltration, provides safe and etiological treatment, and reduces side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121059609A_ABST
    Figure CN121059609A_ABST
Patent Text Reader

Abstract

The invention discloses application of sitagliptin in preparation of a medicine for treating Graves eye diseases, and belongs to the field of biological medicine. The invention discloses the application of sitagliptin in preparation of the medicine for treating Graves eye diseases for the first time, and sitagliptin can improve expression of CD4 + CTL cytotoxic functional molecules and improve eye symptoms, extraocular muscle thickening and fibrosis, orbit fat neogenesis and orbit T lymphocyte infiltration of mice; the mouse spleen CD4 + CTL cell proportion is improved; in addition, the thyroid hormone level, thyroid hyperplasia and hypertrophy and lymphocyte infiltration of mice can be improved. Sitagliptin is a clinically common hypoglycemic drug, and is perfect in safety database, small in side effect and easy to popularize clinically. Therefore, the experimental result of the invention fully supports the new application of sitagliptin in treating Graves eye diseases, and is a new direction worthy of exploration for treating Graves eye diseases due to strong clinical operability.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of biological medicine, and particularly relates to application of sitagliptin in preparation of a medicine for treating Graves' ophthalmopathy. BACKGROUND

[0002] Graves' disease (GD) is also known as toxic diffuse goiter, which is an organ-specific autoimmune disease. Thyroid-related eye disease, also known as Graves' ophthalmopathy (GO), is a common complication of autoimmune disease, and its main pathological features include orbital fibrosis, extraocular muscle thickening, orbital fat neogenesis, and CD4+ CTL cell infiltration. The current clinical treatment methods have problems such as low efficiency and large side effects, and lack effective treatment methods targeting the cause. The current clinical treatment methods for Graves' ophthalmopathy mainly include high-dose intravenous injection of glucocorticoids, retrobulbar radiotherapy, I131 treatment, and surgical treatment. These treatment methods are symptomatic treatments for patients prone to pathological changes, and have problems such as low efficiency, high recurrence rate, and large side effects. At present, there is a lack of safe and effective etiological treatment methods, which seriously affect the physical and mental health of patients.

[0003] Research has found that CD4+ toxic T lymphocytes play a key role in disease development, and they cause tissue damage by releasing pro-fibrotic factors. CD4+ T cells have been reported to be the most abundant immune cell type infiltrating the orbital tissue of GO patients, and they are involved in the initiation of local inflammatory response and the process of tissue remodeling. Based on the results of our previous CD4+ T cell single-cell sequencing study of GD and GO patients, terminally differentiated CD4+ toxic T lymphocytes (CD4+ CTL) with high expression of granzyme and perforin are a specific CD4+ T cell subpopulation of GO patients. They can infiltrate the orbital tissue of GO patients, release inflammatory factors such as IFN-γ, pro-fibrotic factors such as TGF-β and granzyme B (GZMB), activate orbital fibroblasts, and participate in the process of ocular inflammation and fibrosis. CD26 is a transmembrane protein present on the surface of many cells (such as T cells, endothelial cells, and epithelial cells). We found that terminally differentiated CD4+ CTLs significantly lower express CD26 molecules compared to intermediate differentiated CD4+ CTLs. Our previous research found that stimulating CD4+ CTLs with a CD26 agonist can promote GZMB expression, while using the CD26 inhibitor sitagliptin can inhibit GZMB expression. Sitagliptin is a commonly used hypoglycemic drug in clinical practice, and its core mechanism of action is to inhibit dipeptidyl peptidase-4 (DPP-4), which is an alias of CD26 protein in the state of emphasizing its enzyme activity. Therefore, as a CD26 inhibitor, sitagliptin can inhibit the toxicity and fibrosis-promoting function of CD4+ CTL, thereby achieving the effect of improving Graves ophthalmopathy. At present, sitagliptin is widely used in the treatment of diabetes, but its application in Graves ophthalmopathy is still blank. SUMMARY

[0004] In order to overcome the shortcomings of the prior art, the purpose of the present application is to provide the use of sitagliptin in the preparation of a drug for treating Graves ophthalmopathy.

[0005] In order to achieve the above purpose, the technical scheme adopted by the present application is as follows: The present application provides the use of sitagliptin and its pharmaceutically acceptable salts in the preparation of a drug for treating Graves ophthalmopathy.

[0006] Further, the present application also proposes that the drug is a drug for improving orbital fibrosis. By taking sitagliptin and its pharmaceutically acceptable salts as active ingredients, the core mechanism of abnormal activation of orbital fibroblasts in the pathological process of Graves ophthalmopathy is intervened. In view of the CD4+ CTL specific infiltration phenomenon found in the orbital tissue of GO patients by single cell sequencing, the characteristics of sitagliptin as a CD26 inhibitor are used to regulate the fibrosis process by adjusting the functional state of CD4+ CTL, which is different from the non-specific anti-inflammatory effect of traditional glucocorticoid therapy, and has the characteristics of precise intervention of pathological links.

[0007] Further, the present application also proposes that the drug is a drug for improving orbital adipogenesis. Sitagliptin inhibits the pathological process of orbital adipogenesis. The characteristic change of Graves ophthalmopathy includes the differentiation of orbital fibroblasts into adipocytes, resulting in abnormal proliferation of adipose tissue. As a CD26 inhibitor, sitagliptin can block the expansion of CD4+ CTL cells and release pro-inflammatory factors, thereby inhibiting the activation of orbital fibroblasts and the differentiation process of orbital fibroblasts into adipocytes. By targeting CD4+ CTL, the drug directly intervenes the upstream driving factor of adipogenesis, rather than simply relieving symptoms, and achieves etiological treatment of orbital adipose volume increase. Compared with the surgery or hormone treatment for adipose hyperplasia in the prior art, this scheme has a more precise target and a lower risk of side effects through regulation at the molecular mechanism level.

[0008] Further, the present application also proposes that the drug is a drug for improving CD4+ CTL cell infiltration in the thyroid and the orbit. By inhibiting the infiltration of CD4+ CTL cells in the thyroid and the orbit, the pathological damage of the release of pro-inflammatory factors and pro-fibrotic factors to the local tissue is blocked. Specifically, the drug reduces the migration ability of CD4+ CTL cells to the thyroid follicular epithelium and the orbital fibroblasts by targeting the toxic function of CD4+ CTL cells, thereby reducing the direct destructive effect of effect molecules such as GZMB and IFN-γ on the target tissue. The double regulation of the thyroid and the orbit, the two key affected organs, not only inhibits the abnormal hormone level caused by the thyroid autoimmune reaction, but also blocks the adipogenesis and fibrosis process caused by the activation of orbital fibroblasts.

[0009] Further, the present application also proposes that the drug is a drug for improving thyroid hormone level. The abnormal thyroid hormone level is regulated by sitagliptin. Graves ophthalmopathy is closely related to hyperthyroidism, and the increase of thyroid hormone level is an important pathological feature of the disease. As a CD26 inhibitor, sitagliptin reduces the lymphocyte infiltration and abnormal proliferation of follicular epithelial cells in the thyroid tissue by inhibiting the toxic function of CD4+ CTL cells, thereby improving the thyroid hormone secretion function. Specifically, it reduces the serum total thyroxine (TT4) level, restores the normal morphology of the thyroid follicle, and makes the colloid content in the follicular lumen tend to normal distribution. This mechanism of action is different from the traditional direct intervention means for thyroid hormone synthesis, and it is through the immune regulation pathway to achieve the overall improvement of thyroid function.

[0010] Further, the present application also proposes that the drug is a drug for improving abnormal expansion of CD4+ CTL in the spleen. By designing the drug to improve the abnormal expansion of CD4+ CTL in the spleen, the abnormal expansion of CD4+ CTL cells in the spleen, which is the core pathological link, is inhibited, and the progress of Graves ophthalmopathy is blocked from the source of the immune system. By regulating the abnormal immune response in the spleen, a peripheral immune organ, the number of CD4+ CTL cells with cytotoxicity and pro-fibrotic function is reduced, thereby indirectly inhibiting the migration and infiltration of such cells to the thyroid and orbital tissues, and finally achieving the effect of systemically controlling the development of the disease.

[0011] Further, the present application also proposes that the pharmaceutically acceptable salt of sitagliptin is sitagliptin hydrochloride.

[0012] The technical scheme limits the pharmaceutically acceptable salt of sitagliptin to hydrochloride, clearly defines the specific chemical form of the active ingredient. Sitagliptin hydrochloride, as a specific salt type of sitagliptin, has higher stability and solubility, which can ensure the activity of the active ingredient during preparation and use, thereby improving the bioavailability and therapeutic effect of the drug preparation. Selecting hydrochloride as the salt type of sitagliptin not only matches the mechanism of inhibiting the cytotoxic function of CD4+ CTL cells, but also enhances the intervention ability on the pathological process related to Graves' ophthalmopathy, such as inhibiting orbital fibrosis, reducing CD4+ CTL cell infiltration and other core treatment goals, by optimizing the physical and chemical properties of the drug.

[0013] Further, the present application also proposes a pharmaceutical composition for treating Graves' ophthalmopathy, which comprises sitagliptin and its pharmaceutically acceptable salt as an active ingredient.

[0014] Further, the present application also proposes that the pharmaceutical composition for treating Graves' ophthalmopathy is prepared into tablets, powders, injections, capsules, suspensions, pastes, gels, sustained-release agents or microspheres by adding or not adding pharmaceutically acceptable adjuvants.

[0015] The technical scheme realizes the optimization of clinical application of the therapeutic drug through the design of various dosage forms. Preparing the active ingredient into tablets, capsules and other solid dosage forms can improve the convenience of oral administration; injection dosage forms are suitable for rapid intervention of acute symptoms; semi-solid dosage forms such as suspensions and gels are beneficial to local administration of the eye; sustained-release agents and microsphere preparations can prolong the action time of the drug. The preparation method with or without adjuvants not only retains the possibility of direct molding of the raw material drug, but also allows the adjustment of the dissolution rate and bioavailability of the drug through adjuvants. The combination of various dosage forms covers the differentiated needs of different disease stages and patient groups, solving the medication limitation problem caused by the single dosage form of the traditional treatment method.

[0016] Compared with the prior art, the present application has the following beneficial effects: The present application first discloses the Graves' ophthalmopathy pharmaceutical application of sitagliptin, which can improve the expression of CD4+ CTL cytotoxicity function molecules, improve the eye symptoms, extraocular muscle thickening and fibrosis, orbital fat neogenesis, and orbital T lymphocyte infiltration of mice; and improve the CD4+ CTL cell proportion of mice; in addition, it can also improve the thyroid hormone level, thyroid hyperplasia and lymphocyte infiltration of mice. Sitagliptin is a commonly used hypoglycemic drug in clinical practice, with a perfect safety database, small side effects and easy promotion in clinical practice. Therefore, the experimental results of the present application fully support the new application of sitagliptin in treating Graves' ophthalmopathy, and since the clinical operability is strong, it is a new direction for exploring Graves' ophthalmopathy treatment. BRIEF DESCRIPTION OF DRAWINGS

[0017] Figure 1 Grouping of mice and flow chart of GO modeling, drug intervention time points; Figure 2 Appearance of model group mice with symptoms of eye disease and appearance of control group, sitagliptin group mice; Figure 3 Comparison chart of coronal and sagittal magnetic resonance results of mouse eyes, wherein a is extraocular muscle, b is optic nerve, c is cerebrospinal fluid, and d is Harderian gland; Figure 4 Comparison chart of extraocular muscle fibrosis volume, perioptic adipose tissue area, and infiltrated CD3+ T cell number in the orbit of three groups of mice; Figure 5 Comparison chart of food intake to body weight ratio of three groups of mice; Figure 6 Comparison chart of TT4 level in serum of three groups of mice; Figure 7 Comparison chart of thyroid pathology and CD3+ T lymphocyte infiltration number of three groups of mice; Figure 8 Comparison chart of CD4+ CTL cell proportion in spleen cells of three groups of mice; Figure 9 Comparison chart of CD4+ CTL cell infiltration in thyroid tissue and orbital tissue of three groups of mice. DETAILED DESCRIPTION

[0018] In order to enable persons skilled in the art to better understand the present application, the technical solutions in the embodiments of the present application will be described clearly and completely below in combination with the accompanying drawings of the embodiments of the present application. Obviously, the described embodiments are only a part of the embodiments of the present application, rather than all the embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by persons skilled in the art without creative labor should fall within the scope of protection of the present application.

[0019] It should be noted that the terms "first", "second", and the like in the specification and claims of the present application and the above-described drawings are used to distinguish similar objects, and do not necessarily indicate a specific order or a chronological sequence. It should be understood that the data thus used can be interchanged under appropriate circumstances, so that the embodiments of the present application described herein can be implemented in an order other than that illustrated or described herein. In addition, the terms "include" and "have" and any variations thereof are intended to cover non-exclusive inclusion, for example, a process, method, system, product, or device that includes a series of steps or units does not necessarily have to be limited to those steps or units clearly listed, but can include other steps or units that are not clearly listed or inherent to the process, method, product, or device.

[0020] The application will be described in further detail below with reference to the drawings: I. Embodiment Embodiment 1 This embodiment proposes the use of sitagliptin and its pharmaceutically acceptable salts in the preparation of a drug for treating Graves' ophthalmopathy.

[0021] Sitagliptin refers to a chemical substance with dipeptidyl peptidase-4 inhibitory activity, which can be realized in the form of its free base or salt with hydrochloric acid. This substance exerts its effect by blocking the cell signaling mediated by CD26 molecules. Pharmaceutically acceptable salts refer to ionized forms that maintain drug activity and meet formulation requirements, which can be realized in the form of hydrochloride, phosphate or sulfate, etc. Such salt forms can improve drug solubility and bioavailability.

[0022] Specifically, sitagliptin inhibits the enzymatic activity of CD26 molecules on the surface of CD4+ CTL cells, reduces the secretion level of granzyme B, and thus blocks the activation of fibroblasts around the optic nerve by these cells. At the same time, by inhibiting the expansion of CD4+ CTL cells and the release of pro-inflammatory factors, it inhibits the activation of orbital fibroblasts to adipocytes, reducing the abnormal enlargement of orbital fat volume. In thyroid tissue, the drug reduces CD4+ CTL infiltration, improves the abnormal proliferation of follicular epithelial cells, and reduces the excessive secretion of thyroid hormones. The choice of drug salt form ensures the stable release of active ingredients in the body fluid environment, maintaining the sustained inhibition of abnormal proliferation of splenic CD4+ CTL.

[0023] Compared with the prior art, sitagliptin, as an approved hypoglycemic drug, has a complete safety database, avoiding unknown risks that may be caused by new immunosuppressants. Compared with the broad-spectrum immunosuppression of glucocorticoids, this scheme precisely targets CD4+ CTL cell subgroups, inhibiting the pathological process while preserving normal immune function. Compared with the invasive treatment of surgical intervention, this drug can achieve systemic treatment through oral or injection, and has a synchronous intervention effect on fibrosis and adipogenesis.

[0024] Through the above technical solutions, the present application realizes multi-target intervention on the core pathological mechanism of Graves' ophthalmopathy, effectively improves the fibrosis thickening of extraocular muscles, the abnormal proliferation of orbital adipose tissue, and the symptoms of hyperthyroidism, while reducing the abnormal expansion level of splenic CD4+ CTL cells, providing a new way for disease treatment with safety and etiological treatment characteristics.

[0025] As a preferred technical solution, this embodiment further proposes the use of a drug for improving orbital fibrosis in the preparation of a drug for treating Graves' ophthalmopathy.

[0026] The improvement of orbital fibrosis refers to the reduction of abnormal deposition of collagen fibers in the extraocular muscle space by inhibiting the secretion of granzyme B by CD4+ toxic T lymphocytes. Specifically, the inhibitor can be used as a CD26 inhibitor to block the pro-fibrotic function of CD4+ toxic T lymphocytes by regulating the activity state of CD4+ toxic T lymphocytes surface molecule CD26 to inhibit the generation and release of granzyme B and other pro-fibrotic factors.

[0027] Specifically, during the pathological process of orbital fibrosis, CD4+ toxic T lymphocytes activate orbital fibroblasts by releasing granzyme B, leading to abnormal accumulation of collagen fibers in the extraocular muscle space. By inhibiting the activity of CD26 molecules, sitagliptin reduces the expression level of granzyme B in CD4+ toxic T lymphocytes, thereby blocking the activation signal transduction pathway of fibroblasts. This mechanism directly targets the specific infiltrating CD4+ toxic T lymphocyte subpopulation in Graves' ophthalmopathy, inhibits the activity of collagen synthetase by regulating its secretion function, and ultimately reduces the fibrotic remodeling of the extraocular muscle tissue.

[0028] As a preferred technical solution, the embodiment further proposes that sitagliptin and its pharmaceutically acceptable salts are used for preparing a drug for improving the thickening and fibrosis of the extraocular muscle.

[0029] The thickening of the extraocular muscle refers to the abnormal increase in the volume of the extraocular muscle tissue caused by abnormal activation of immune cells, which can be detected by magnetic resonance imaging to detect changes in the area of the extraocular muscle region. This phenomenon directly leads to exophthalmos.

[0030] The fibrosis refers to the pathological structural changes caused by the abnormal deposition of collagen in the extraocular muscle space, which can be observed by the Masson staining method to observe the proportion of blue collagen fibers. This pathological process causes a decrease in the elasticity of the extraocular muscle, eye movement disorders, and impaired vision.

[0031] Specifically, this technical solution inhibits the secretion of granzyme B by CD4+ toxic T lymphocytes to block the activation of the pro-fibrotic signaling pathway, thereby inhibiting the differentiation of orbital fibroblasts into myofibroblasts. At the same time, by regulating the functional state of CD4+ toxic T lymphocytes, the activation of orbital fibroblasts is reduced, thereby inhibiting the synthesis and release of hyaluronic acid that can absorb a large amount of water by fibroblasts, and further inhibiting the thickening of the extraocular muscle. This dual mechanism intervenes in the fibrosis formation process at the molecular level and controls the development of pathological thickening at the tissue level.

[0032] As a preferred technical solution, the embodiment further proposes the use of sitagliptin and its pharmaceutically acceptable salts in the preparation of a drug for improving orbital fat neogenesis.

[0033] The improvement of the orbital fat neogenesis refers to inhibiting the differentiation process of the orbital fibroblasts into adipocytes, and can be specifically achieved by using siglitin to block the pro-inflammatory factors released by CD4+ CTL cells, and the process is intervened by regulating the CD26 molecule activity to interfere with the cell signal transduction pathway. The siglitin as a CD26 inhibitor can be specifically achieved by inhibiting the expression of the pro-inflammatory factors of the CD4+ CTL cells, so as to reduce the activation of the orbital fibroblasts and directly act on the upstream regulation link of the fat neogenesis.

[0034] Specifically, the orbital fibroblasts are differentiated into adipocytes under the stimulation of the factors such as IFN-γ secreted by CD4+ CTL, resulting in abnormal increase of the fat volume. The siglitin reduces the release of IFN-γ and other factors by inhibiting the CD26-mediated CD4+ CTL activation, blocks the fibroblast differentiation signal pathway, and thus inhibits the fat neogenesis process. The action mechanism is to intervene the pathological process through the molecular target, rather than simply reducing the formed fat tissue.

[0035] Through the above technical solution, the orbital fat tissue area of the Graves ophthalmopathy model animal can be effectively reduced, and the differentiation of the fibroblasts into adipocytes is inhibited, so as to improve the orbital structure abnormality caused by the fat neogenesis. The technical solution reverses the pathological process through the specific molecular action mechanism, and provides a treatment method with etiological intervention ability for clinical treatment.

[0036] As a preferred technical solution, the embodiment further proposes a drug application for treating Graves ophthalmopathy by inhibiting the infiltration of CD4+ CTL cells in the thyroid and the orbit.

[0037] The CD4+ CTL cell refers to a terminal differentiation period CD4+ toxic T lymphocyte with high expression of granzyme and perforin, which directly destroys the target tissue by releasing effect molecules such as IFN-γ, TGF-β and granzyme B. The infiltration in the thyroid and the orbit refers to the migration of the CD4+ CTL cells to the thyroid follicular epithelium and the surrounding orbital fibroblasts and the initiation of local inflammatory response. The improvement of the infiltration can be achieved by inhibiting the CD4+ CTL cell function mediated by the CD26 molecule, for example, using siglitin to block the enzyme activity of CD26 to reduce the migration ability of CD4+ CTL.

[0038] Specifically, the abnormal aggregation of the CD4+ CTL cells in the thyroid and the orbit releases pro-inflammatory factors and pro-fibrotic factors, resulting in thyroid follicular epithelial hyperplasia and activation of orbital fibroblasts. By inhibiting the CD26 molecule activity, the migration of the CD4+ CTL cells to the target tissue can be reduced, so as to reduce the destructive effect of toxic molecules such as GZMB on the thyroid hormone secretion and the orbital fat neogenesis. The action mechanism simultaneously acts on the two key pathological sites of the thyroid and the orbit, and blocks the vicious cycle of the autoimmune response and the tissue remodeling.

[0039] As a preferred technical solution, the embodiment further proposes an application of sitagliptin and pharmaceutically acceptable salts thereof in preparing a drug for treating Graves ophthalmopathy by improving thyroid hormone levels.

[0040] Among them, improving thyroid hormone levels means that the serum total thyroid hormone content is restored to the normal range by regulating the abnormal function of thyroid follicular epithelial cells and the state of lymphocyte infiltration. Specifically, it can be achieved by inhibiting CD4+ CTL-mediated thyroid tissue inflammatory response, which reduces the expression of inflammatory factors by blocking the activity of CD26 molecules, thereby reducing the pathological changes of thyroid follicle structure.

[0041] Among them, sitagliptin and pharmaceutically acceptable salts thereof refer to compounds with dipeptidyl peptidase-4 inhibitory activity or stable salts formed with acids. Specifically, it can be achieved by using sitagliptin hydrochloride as an active ingredient, which regulates the pro-inflammatory function of CD4+ CTL by inhibiting the function of CD26 molecules.

[0042] Specifically, sitagliptin reduces lymphocyte infiltration and abnormal proliferation of follicular epithelial cells in thyroid tissue by inhibiting the release of granzyme B and pro-inflammatory factors from CD4+ CTL, thereby restoring the homeostasis of thyroid hormone synthesis and secretion. This mechanism of action is different from traditional drugs that directly inhibit thyroid peroxidase or block thyroid hormone synthesis. Instead, it indirectly improves the distribution of colloid in thyroid follicle lumen and the morphology of follicular epithelial cells through immunoregulatory pathways, ultimately resulting in a decrease in serum total thyroid hormone levels and normalization of thyroid tissue structure.

[0043] As a preferred technical solution, the embodiment further proposes a technical solution for improving abnormal expansion of splenic CD4+ CTL by drugs.

[0044] Among them, improving the abnormal expansion of splenic CD4+ CTL means inhibiting the abnormal proliferation of CD4+ CTL cells in the spleen. Specifically, it can be achieved by using CD26 inhibitors to intervene in the activation and differentiation process of CD4+ CTL. This feature regulates abnormal immune responses in peripheral immune organs, thereby reducing the number of immune cells with pro-fibrotic and cytotoxic functions from the source.

[0045] Specifically, the technical scheme blocks the abnormal proliferation signal pathway of CD4+ CTL by inhibiting the activity of CD26 molecules, reduces the proportion of CD4+ CTL cells in the spleen, and thus reduces the migration and infiltration of such cells to the thyroid and orbital tissues. In the implementation process, the CD26 inhibitor can act on the CD4+ CTL precursor cells in the spleen to inhibit their differentiation into terminal effector cells, and at the same time, by regulating the expression level of toxic factors such as GZMB, the fibrosis-promoting function of CD4+ CTL is weakened. Thus, a systematic regulation mechanism from the peripheral immune organs to the target organs is formed, effectively controlling the pathological process of Graves ophthalmopathy.

[0046] As a preferred technical scheme, the embodiment further proposes that the pharmaceutically acceptable salt of sitagliptin is sitagliptin hydrochloride.

[0047] Specifically, sitagliptin hydrochloride can inhibit the expression of CD4+ CTL cytotoxic function molecules and block the release of fibrosis-promoting factors, thereby interfering with the activation and differentiation of orbital fibroblasts. The physicochemical properties of the hydrochloride salt optimize the absorption and distribution of the drug in the body, so that the active ingredient can more effectively target the thyroid and orbital tissues and reduce the infiltration of CD4+ CTL cells. The selection of the salt type is adapted to the mechanism of action of sitagliptin in inhibiting the activity of CD26 enzyme, further enhancing the regulation ability on the pathological process of Graves ophthalmopathy.

[0048] Specifically, sitagliptin hydrochloride can inhibit the expression of CD4+ CTL cytotoxic function molecules and block the release of fibrosis-promoting factors, thereby interfering with the activation and differentiation of orbital fibroblasts. The physicochemical properties of the hydrochloride salt optimize the absorption and distribution of the drug in the body, so that the active ingredient can more effectively target the thyroid and orbital tissues and reduce the infiltration of CD4+ CTL cells. The selection of the salt type is adapted to the mechanism of action of sitagliptin in inhibiting the activity of CD26 enzyme, further enhancing the regulation ability on the pathological process of Graves ophthalmopathy.

[0049] Embodiment 2 The application further proposes a pharmaceutical composition for treating Graves ophthalmopathy, which comprises sitagliptin and a pharmaceutically acceptable salt thereof as an active ingredient.

[0050] Specifically, sitagliptin is a dipeptidyl peptidase-4 inhibitor, which can be realized by using its free base or salt compound formed with an acid to regulate the function of CD4+ toxic T lymphocytes by inhibiting the activity of CD26 molecules. The pharmaceutically acceptable salt refers to a soluble salt formed with an inorganic acid or an organic acid, which can be realized by using hydrochloride, phosphate or citrate to improve the solubility and bioavailability of the active ingredient.

[0051] Specifically, the pharmaceutical composition blocks the expression of granzyme B in terminally differentiated CD4+ toxic T lymphocytes through the inhibition of CD26 molecule enzymatic activity by sitagliptin, thereby inhibiting the activation of orbital fibroblasts and the release of pro-fibrotic factors. The pharmaceutically acceptable salt form enhances the delivery efficiency of the active ingredient in the target tissue by optimizing the dispersion state of the drug molecule in the body fluid. The composition targets the core pathological aspects of orbital fibrosis, adipogenesis and immune cell infiltration in Graves ophthalmopathy, and achieves therapeutic intervention at the etiological level by regulating the function of CD4+ toxic T lymphocytes.

[0052] In some embodiments, the pharmaceutical composition can be prepared as an oral solid preparation, such as a tablet or capsule containing sitagliptin hydrochloride, with a unit dose ranging from 25 to 100 mg; or as a lyophilized powder for injection, such as a sterile powder formed by lyophilizing sitagliptin sodium phosphate and mannitol, which is reconstituted with water for injection before use.

[0053] The application further proposes that the pharmaceutical composition for treating Graves ophthalmopathy be prepared into tablets, powders, injections, capsules, suspensions, pastes, gels, sustained-release preparations or microspheres with or without the addition of pharmaceutically acceptable excipients. Among them, the tablet refers to a solid preparation prepared by mixing the active ingredient with a disintegrant and a binder through a tabletting process, which can specifically use microcrystalline cellulose as a filler and croscarmellose sodium as a disintegrant, and is suitable for oral administration. The powder refers to a powder-like preparation formed by crushing the raw material drug, which can specifically be prepared by spray drying technology, and is convenient for adjusting the dosage. The injection refers to a liquid or lyophilized powder type prepared by a sterilization process, which can specifically be achieved by a sterile filling technology, and is suitable for intravenous or intramuscular injection. The sustained-release preparation refers to a preparation that controls the release rate of the drug through coating technology or matrix material, which can specifically use ethyl cellulose as a sustained-release coating material to prolong the action time of the drug.

[0054] Specifically, tablets and capsules improve patient convenience through standardized dosage design, injections meet the needs of rapid onset in the acute phase, suspensions and gels directly act on the affected area of the eye through local administration. The sustained-release preparation maintains an effective blood drug concentration by controlling the drug release curve, and the microsphere preparation uses biodegradable materials to achieve long-acting sustained release. The addition of excipients can adjust the drug dissolution behavior, such as hydroxypropyl methylcellulose as a binder to improve tablet formability, and mannitol as a lyophilization protective agent to improve the stability of the injection.

[0055] Compared with the prior art, the conventional Graves ophthalmopathy treatment drugs are mostly limited to oral tablets or intravenous injection dosage forms, which cannot meet the differentiated needs of different disease stages for administration routes. The present technology solves the medication limitation problem caused by a single dosage form by constructing a multi-dosage form system, so that the drug can be adapted to various treatment scenarios such as ocular local administration, systemic administration and sustained-release administration.

[0056] II. Experimental Section 1. Experimental apparatus 6-week-old female inbred BALB / C mice (purchased from the Animal Center of Xi'an Jiaotong University), sitagliptin (purchased from APExBIO company), human TSHR289 gene overexpression purified adenovirus (Ad-TSHR) and green fluorescent protein overexpression control adenovirus (Ad-EGFP) (purchased from Shanghai Hanheng Biotechnology Co., Ltd.), thyroid hormone radioimmunoassay kit (purchased from Tianjin Union Pharmaceutical Technology Co., Ltd.). 2. Experimental method 1) Grouping and feeding: the mice were randomly divided into control group, model group and sitagliptin intervention group according to body weight, and were fed in SPF animal room.

[0057] 2) Modeling (adenovirus injection): as shown in the table, the experimental starting point was the 0th week, and the mice were injected intramuscularly at the 0th, 3rd, 6th, 10th, 14th, 18th and 22nd weeks. The model group and the sitagliptin intervention group were injected with Ad-TSHR; the control group was injected with Ad-EGFP. Figure 1

[0058] 3) Drug intervention: from the 11th week, the sitagliptin intervention group was given sitagliptin (90 mg / kg / d) by oral gavage. The control group and the model group were given carrier solution (0.5% CMC-Na and 4% DMSO) by gavage. The intervention lasted until the end of the 24th week experiment.

[0059] 4) Body weight and food intake monitoring: the body weight of the mice and the feed consumption per cage were weighed every week.

[0060] 5) Eye observation: the eyes of the mice were observed during the experiment.

[0061] 6) Sampling: at the end of the 24th week experiment, the mice were euthanized, and blood, thyroid, orbital bone and spleen were collected.

[0062] 3. Observation index 1) Food weight ratio: according to the body weight and food intake of the mice every week, the daily food intake (g / kg body weight / day) was calculated.

[0063] ​2) Extraocular muscle area: At week 24, the head of anesthetized mice was scanned using a 9.4T magnetic resonance imaging instrument to obtain coronal and sagittal T2-weighted imaging (T2WI) results of the extraocular muscle.

[0064] 3) Serum total thyroid hormone (TT4) level: The serum was separated, and the TT4 concentration was determined using a radioimmunoassay kit. The mean + 2 standard deviation (Mean + 2SD) of the TT4 detection value of the control group mice was used as the upper limit of the normal value, and values exceeding this value were determined to be elevated TT4.

[0065] 4) Thyroid hyperplasia and lymphocyte infiltration: Sampling and sectioning: The thyroid gland was cut from the larynx to the seventh cartilage level of the trachea (located on both sides of the thyroid cartilage and trachea, consisting of left and right lobes and isthmus). Paraffin embedding and sectioning were performed.

[0066] HE staining: HE staining was performed to observe the pathological changes of the thyroid.

[0067] Immunohistochemistry: CD3 staining was performed, and after slide scanning, the thyroid tissue was located under 40x magnification, and 3 non-repeated fields were randomly selected to count the number of brown CD3+ T cells.

[0068] Immunofluorescence staining: CD4 and GZMB immunofluorescence staining was performed, and the sections were observed under a fluorescence microscope and images were collected. The thyroid tissue was located under 40x magnification, and 3 non-repeated fields were randomly selected to count the number of CD+ CTL cells.

[0069] 5) Orbital pathology: Sampling and processing: Orbital bone was taken and decalcified before paraffin embedding.

[0070] Sectioning and staining: Coronal sectioning was performed, and every 0.8mm was taken to cross the whole orbital section, and Masson's trichrome staining was performed (collagen fibers appear blue). The level was selected using the optic nerve as a marker, HE staining was performed to observe the retrobulbar fat area, CD3 staining was performed to observe the retrobulbar T cell infiltration, and CD4 and GZMB immunofluorescence staining was performed to observe the CD4+ CTL infiltration in the orbit.

[0071] Analysis: Image acquisition was performed by slide scanning, and ImageJ software was used to analyze the pigment block, calculate the volume of retrobulbar fibrosis and fat area, and locate the orbital tissue under 40x magnification, and 3 non-repeated fields were randomly selected to count the number of CD3+ T cells and CD4+ CTL cells.

[0072] 6) Spleen cell flow cytometry analysis: Sample preparation: The spleen was ground and filtered to obtain a single cell suspension, and red blood cells were lysed.

[0073] Staining protocol: surface staining of CD4, GZMB staining after fixation and membrane rupture.

[0074] Detection: the proportion of each stained cell subpopulation was detected using a Novocyte flow cytometer.

[0075] 4. Experimental results 1) Observation of mouse orbital symptoms after sitagliptin intervention The results of the mouse eye appearance are shown in Figure 2 The model mice showed typical symptoms of eyelid edema, photophobia, tearing, and inflammatory scab eye disease, while the mice after sitagliptin intervention showed no obvious changes in eye disease.

[0076] 2) Magnetic resonance examination of mouse eyes after sitagliptin intervention The results of the coronal and sagittal eye magnetic resonance are shown in Figure 3 The white arrow labeled b indicates the low signal area of the mouse optic nerve, the high signal area labeled c around the optic nerve is the cerebrospinal fluid around the optic nerve, and the higher signal area labeled d is the Harder's gland of the mouse. The low signal area between the c and d areas is the extraocular muscle of the mouse. The extraocular muscle area of the GO model mice was significantly larger than that of the control mice, and the extraocular muscle area of the mice after sitagliptin intervention was improved.

[0077] 3) Detection of mouse orbital fibrosis, adipogenesis, and T lymphocyte infiltration after sitagliptin intervention The results are shown in Figure 4 Compared with the control group, a large number of collagen fibers dyed blue appeared between the intermyofibrillar spaces of the model mice, and after sitagliptin treatment, the mouse extraocular muscle fibrosis was significantly improved. The area of the fat tissue around the optic nerve of the model mice increased significantly, and after sitagliptin intervention, the orbital tissue area of the mice decreased significantly. There was obvious CD3+ T lymphocyte infiltration in the orbital fat tissue of the model mice, and after sitagliptin intervention, the CD3+ T lymphocyte infiltration in the mouse orbit was significantly improved.

[0078] 4) Detection of food intake to body weight ratio of mice after sitagliptin intervention Due to the promotion of food intake behavior, significant increase in basal metabolic rate, and increased intestinal peristalsis caused by hyperthyroidism, the mice showed increased food intake and decreased body weight. As shown in Figure 5 Before 11 weeks, as the modeling process progressed, the food intake to body weight ratio of the model mice showed a gradually increasing trend. Sitagliptin treatment began at week 11, and in the first week of treatment, the food intake to body weight ratio of the mice in the drug intervention group was slightly lower than that of the model group. In the next two weeks, it rapidly and significantly decreased, and in the following weeks, it showed a slow downward trend until the end of the experiment.

[0079] 5) Measurement of thyroid hormone in mice after intervention of sitagliptin The results of TT4 level in serum of mice are shown in Figure 6 The TT4 of mice in model group was significantly increased; the TT4 of mice after intervention of sitagliptin was significantly decreased.

[0080] 6) Observation of thyroid hyperplasia and lymphocyte infiltration in thyroid of mice after intervention of sitagliptin The results of HE staining of thyroid of mice are shown in Figure 7 The thyroid follicular epithelial cells of mice in control group presented flat shape, and the content of colloid in follicle was rich and uniformly distributed; the thyroid follicular epithelial cells of mice in model group were obviously hyperplastic and hypertrophic, and presented high columnar change, and the arrangement was disordered, and the colloid content in follicle cavity was obviously reduced and unevenly distributed. The thyroid hyperplasia of mice after intervention of sitagliptin was obviously improved.

[0081] The results of CD3 immunohistochemical staining of thyroid of mice are shown in Figure 7 Compared with the mice in control group, the number of CD3+T cells infiltrated in thyroid tissue of mice in model group was obviously increased. After intervention of sitagliptin, the number of CD3+T cells infiltrated in thyroid of mice was obviously decreased. 7) Measurement of proportion of CD4+CTL cells in spleen of mice after intervention of sitagliptin The results are shown in Figure 8 Compared with the mice in control group, the CD4+CTL in spleen of mice in model group was obviously abnormally expanded, and the proportion of CD4+CTL was obviously decreased after treatment of sitagliptin.

[0082] 8) Measurement of CD4+CTL cell infiltration in thyroid and orbital tissue of mice after intervention of sitagliptin The results are shown in Figure 9 The CD4+CTL (CD4+GZMB+) cells infiltrated in thyroid and orbital of mice in model group were obviously increased, and the CD4+CTL cells infiltrated in both of them were obviously decreased after intervention of sitagliptin.

[0083] According to the above results, the following conclusions can be drawn: the intervention of sitagliptin in Graves' mouse model improves the eye symptoms, the thickening and fibrosis of extraocular muscles, the orbital fat neogenesis, the orbital T lymphocyte infiltration of mice; improves the food weight ratio, the thyroid hormone level, the thyroid hyperplasia and hypertrophy, the lymphocyte infiltration of mice; and improves the abnormal expansion of CD4+CTL in spleen and the CD4+CTL cell infiltration in thyroid and orbital of mice.

[0084] The above merely illustrates the technical idea of the present application, and cannot limit the protection scope of the present application. Any modification made according to the technical idea of the present application on the basis of the technical scheme falls within the protection scope of the present application.

Claims

1. Use of sitagliptin and pharmaceutically acceptable salts thereof in the preparation of a medicament for treating Graves ophthalmopathy.

2. Use according to claim 1, wherein The medicament is a medicament for improving fibrosis of the orbit.

3. Use according to claim 2, wherein the compound is ###0002### The medicament is a medicament for improving hypertrophy and fibrosis of the extraocular muscles.

4. The use according to claim 1, wherein The medicament is a medicament for improving adipogenesis of the orbit.

5. The use according to claim 1, wherein the compound is ###0002### The medicament is a medicament for improving CD4+ CTL cell infiltration in the thyroid and the orbit.

6. The use according to claim 1, wherein The medicament is a medicament for improving thyroid hormone levels.

7. Use according to claim 6, wherein The medicament is a medicament for improving hypertrophy of the thyroid.

8. The use according to claim 1, wherein The medicament is a medicament for improving abnormal expansion of CD4+ CTL in the spleen.

9. A pharmaceutical composition for treating Graves ophthalmopathy, characterized by, The pharmaceutical composition comprises sitagliptin and pharmaceutically acceptable salts thereof as an active ingredient, and the sitagliptin pharmaceutically acceptable salt is sitagliptin hydrochloride.

10. The pharmaceutical composition for treating Graves ophthalmopathy according to claim 9, wherein The pharmaceutical composition is prepared into tablets, powders, injections, capsules, suspensions, pastes, gels, coating agents, drug film agents, sustained-release agents, or microspheres with or without the addition of pharmaceutically acceptable adjuvants.